1.DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome.
Huong Thi TRAN ; Hee Nam KIM ; Il Kwon LEE ; Yeo Kyeoung KIM ; Jae Sook AHN ; Deok Hwan YANG ; Je Jung LEE ; Hyeoung Joon KIM
Journal of Korean Medical Science 2011;26(2):207-213
DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients. In concordance with the clinical response, a lack of or decreased methylation in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed. The mRNA expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that methylation changes contribute to disease pathogenesis and may serve as marker to monitor the efficacy of treatments.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Azacitidine/*pharmacology/*therapeutic use
;
DNA Methylation/*drug effects
;
DNA Modification Methylases/antagonists & inhibitors/metabolism
;
Enzyme Inhibitors/*pharmacology/*therapeutic use
;
Female
;
Genes, Tumor Suppressor
;
Humans
;
Male
;
Middle Aged
;
Myelodysplastic Syndromes/*drug therapy/*genetics
;
Young Adult
2.Clinical characteristics and prognosis according to the classification of myelodysplastic syndrome.
Hyun Woo LEE ; Hyeoung Il KIM ; Jae Myoung CHOI ; Seok Yun KANG ; Jun Ho JANG ; Joon Seong PARK ; Jin Hyuk CHOI ; Ho Yeong LIM ; Hugh Chul KIM
Korean Journal of Medicine 2006;70(3):253-260
BACKGROUND: Myelodysplastic syndromes (MDS) are clonal hematologic stem cell disorders characterized clinically and morphologically by ineffective hematopoiesis. A consensus-defined French-American-British (FAB) classification and International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in MDS has been developed, but its prognostic value in a large and independent series remains unproven. So we investigate clinical characteristics and prognosis of MDS, according to French-American-British (FAB) classification and International Prognostic Scoring System (IPSS). METHODS: A retrospective analysis of 50 patients who were diagnosed as myelodysplastic syndrome at Ajou University Hospital was performed from November, 1994 to April, 2003. The patients with secondary MDS were excluded. All patients were classified according to the FAB classification and calculated prognostic scores for IPSS. Patients were evaluated for clinical features and for blood and bone marrow findings at the time of diagnosis, and were followed up for survival and leukemic progression. Survival curves were based on the Kaplan-Meier method. All reported p values less than or equal to 0.05 were regarded as stastistically significant. RESULTS: The peak age was in the fifth decade and the male to female ratio was 1.5:1. RA (36%) was observed most frequently. Thereafter, RAEB-t (26%), RAEB (24%), RARS (12%) and CMML (2%) were observed, respectively. The initial symptoms on admission were fever (24%), dizziness and headache (16%), general weakness (16%), hemorrhage (14%), dyspnea (12%), abdominal pain (4%) and vomiting (4%). Cytogenetic studies were performed in 34 patients with MDS. They were classified as good, intermediate, poor group by chromosome score of IPSS. The median survival was 16.4 months for the good group, 15 months for the intermediate, 10.3 months for the poor. The median survival according to FAB classified groups were RA (33.8 mo), RARS (12.5 mo), RAEB (16.4 mo), RAEB-t (6.7 mo) and CMML (1.3 mo). Survival according to IPSS scoring system were 67.2 months for low, 27.1 months for intermediate-1, 10.3 months for intermediate-2 and 6.0 months for high groups. These data were statistically significant (p<0.05). CONCLUSIONS: In our experiencies, FAB and IPSS classification would be good predictors in clinical outcomes. But, because of the heterogeneity of MDS, large multicenter studies will be needed to define the issue of a new classification for these disorders.
Abdominal Pain
;
Anemia, Refractory, with Excess of Blasts
;
Bone Marrow
;
Classification*
;
Cytogenetics
;
Diagnosis
;
Dizziness
;
Dyspnea
;
Female
;
Fever
;
Headache
;
Hematopoiesis
;
Hemorrhage
;
Humans
;
Male
;
Myelodysplastic Syndromes*
;
Population Characteristics
;
Prognosis*
;
Retrospective Studies
;
Stem Cells
;
Vomiting
3.Prevalence of Oral Microbes in the Saliva of Oncological Patients.
Mi Sun KANG ; Jong Suk OH ; Hyeoung Joon KIM ; Hee Nam KIM ; Il Kwon LEE ; Hong Ran CHOI ; Ok Joon KIM ; Young Jong KO ; Won Bong LIM ; Hong Ju PARK ; Min Gi YU ; Kyung Yi CHUNG ; Seon Mi KIM ; Hoi Soon LIM
Journal of Bacteriology and Virology 2009;39(4):277-285
This study examined the prevalence of oral microbes in the saliva of oncological patients and healthy subjects. PCR was used to assess the frequency of oral microbes including 3 cariogenic bacteria, 5 periodontopathic bacteria and 4 Candida species in the saliva of 104 oncological patients and 52 healthy subjects. Among these microorganims, Streptococcus mutans, Fusobacterium nucleatum and Candida albicans were most frequently detected in both groups. There were no significant differences in the prevalence of cariogenic bacteria between the patient and healthy groups, whereas significant differences in the frequency of Porphyromonas gingivalis and Tannerella forsythia were observed between the two groups (p < 0.05). The prevalence of all five periodontopathogens was higher in the healthy group than in the patient group. The prevalence of C. albicans in patients was significantly higher than that of healthy group (p < 0.05). In conclusion, there were significant differences in the prevalence of P. gingivalis, T. forsythia and C. albicans between the oncological patient group and healthy group.
Bacteria
;
Candida
;
Candida albicans
;
Forsythia
;
Fusobacterium nucleatum
;
Humans
;
Polymerase Chain Reaction
;
Porphyromonas gingivalis
;
Prevalence
;
Saliva
;
Streptococcus mutans
4.Dermatomyositis Associated with Cancer of Unknown Primary Site.
Hyung Il KIM ; Sung Hoon CHUNG ; Jun Eul HWANG ; Sang Ho KIM ; Jae Sook AHN ; Duk Hwan YANG ; Yoe Kyeoung KIM ; Sook Jung YUN ; Sang Hee CHO ; Je Jung LEE ; Ik Joo CHUNG ; Hyeoung Joon KIM
Journal of Korean Medical Science 2007;22(Suppl):S174-S177
Dermatomyositis (DM) is an uncommon inflammatory myopathy with characteristic rash accompanying, or more often preceding, muscle weakness. There is a well-recognized association between DM and several cancers, such as ovarian cancer, breast cancer, melanoma, colon cancer, and non-Hodgkin lymphoma. We report the first case of cancer of unknown primary site associated with DM. A 62-yr-old woman presented to us with both shoulder painful swelling and facial edema. She was diagnosed previously as cancer of unknown primary site, histologically confirmed with squamous cell carcinoma in a pelvic mass. For the following days, she complained of erythematous face followed by progressive weakness of the proximal muscles of upper and lower limbs. The laboratory tests showed an increased muscle enzyme and acute phase reactants. The electromyogram showed the typical findings of DM. After the treatment with high dose steroid and methotrexate, the proximal motor weakness improved, and she received palliative radiation therapy.
Carcinoma, Squamous Cell/complications/diagnosis/pathology
;
Dermatomyositis/*complications/diagnosis/pathology/therapy
;
Female
;
Humans
;
Middle Aged
;
Neoplasms, Unknown Primary/*complications/diagnosis/pathology
5.Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.
Hyun Woo CHOI ; Myung Geun SHIN ; Hyeoung Joon KIM ; Il Kwon LEE ; Ju Hyun YUN ; Hye Ran KIM ; Yeo Kyeoung KIM ; Hyeong Kee YUN ; Duck CHO ; Seung Jung KEE ; Jong Hee SHIN ; Soon Pal SUH ; Dong Wook RYANG
The Korean Journal of Laboratory Medicine 2006;26(4):249-254
Biphenotypic acute leukemia (BAL) is a subtype of leukemia of ambiguous lineage in the World Health Organization classification system. About one third of the cases have the Philadelphia chromosome, and some cases are associated with other structural abnormalities involving 11q23. BAL is known to have a poor prognosis in both children and adults. According to the previously reported BAL cases with positive BCR-ABL fusion gene, most of the BCR-ABL mRNA transcript type was e1a2. So, we describe here a 30-year-old adult BAL case with the karyotype 46,XY,t(9;22)(q34;q11.2) resulting in a very rare b3a2 type of BCR-ABL mRNA transcript.
Adult
;
Child
;
Classification
;
Humans
;
Karyotype
;
Leukemia
;
Leukemia, Biphenotypic, Acute*
;
Philadelphia Chromosome
;
Prognosis
;
RNA, Messenger*
;
World Health Organization
6.Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia.
Soo Mee BANG ; Jeong Yeal AHN ; Jiyoon PARK ; Se Hoon PARK ; Jinny PARK ; Eun Kyung CHO ; Dong Bok SHIN ; Jae Hoon LEE ; Sook Jin YOO ; In Sang JEON ; Yeo Kyeoung KIM ; Hyeoung Joon KIM ; Hee Nam KIM ; Il Kwon LEE ; Hyoung Jin KANG ; Hee Young SHIN ; Hyo Seop AHN
Journal of Korean Medical Science 2008;23(5):833-837
FLT3 mutations are common genetic changes, and are reported to have prognostic significance in acute myeloid leukemia (AML). The FLT3 internal tandem duplication (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD) were analyzed by polymerase chain reaction (PCR) in the genomic DNA of Korean patients with AML at diagnosis and during follow-up. There were 226 patients with AML enrolled between March 1996 and August 2005. The incidence of ITD and TKD at diagnosis was 13% (29/226) and 3% (6/226). When compared to Western and other Asian patients with AML, Korean patients had a lower frequency by about two-thirds of ITD and TKD. Among the non-M3 cases (N=203), the patients with an ITD had a significantly shorter event-free survival when compared with those without an ITD (p=0.0079). Among 54 relapsed patients, 9 patients had the FLT3 ITD at diagnosis. Six patients demonstrated a reappearance of the ITD and 3 patients remained negative at relapse. One patient, among 45 patients who relapsed, had a negative baseline ITD but acquired a de novo ITD at relapse. There were 101 samples from 93 patients in remission; they were all negative for an ITD. Among 34 patients who failed to achieve a remission, five patients had a persistent ITD and one patient had a de novo ITD. These results support the concept of resistance of FLT3 ITD leukemic clones to chemotherapy. Therefore, effective therapy with FLT3 targeting agents may improve the prognosis of non-M3 AML patients with the FLT3 mutation.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Child
;
Child, Preschool
;
Disease-Free Survival
;
Female
;
*Gene Expression Regulation, Neoplastic
;
Humans
;
Infant
;
Infant, Newborn
;
Korea
;
Leukemia, Myeloid, Acute/*genetics
;
Male
;
Middle Aged
;
*Mutation
;
Prognosis
;
Recurrence
;
Remission Induction
;
fms-Like Tyrosine Kinase 3/*genetics
7.Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A.
Huong Thi Thanh TRAN ; Hee Nam KIM ; Il Kwon LEE ; Thanh Nhan NGUYEN-PHAM ; Jae Sook AHN ; Yeo Kyeoung KIM ; Je Jung LEE ; Kyeong Soo PARK ; Hoon KOOK ; Hyeoung Joon KIM
Journal of Korean Medical Science 2013;28(2):237-246
SUV39H1 is a histone 3 lysine 9 (H3K9)-specific methyltransferase that is important for heterochromatin formation and the regulation of gene expression. Chaetocin specifically inhibits SUV39H1, resulted in H3K9 methylation reduction as well as reactivation of silenced genes in cancer cells. Histone deacetylase (HDAC) inhibitors inhibit deacetylases and accumulate high levels of acetylation lead to cell cycle arrest and apoptosis. In this study, we demonstrated that treatment with chaetocin enhanced apoptosis in human leukemia HL60, KG1, Kasumi, K562, and THP1 cells. In addition, chaetocin induced the expression of cyclin-dependent kinase inhibitor 2B (p15), E-cadherin (CDH1) and frizzled family receptor 9 (FZD9) through depletion of SUV39H1 and reduced H3K9 methylation in their promoters. Co-treatment with chaetocin and HDAC inhibitor trichostatin A (TSA) dramatically increased apoptosis and produced greater activation of genes. Furthermore, this combined treatment significantly increased loss of SUV39H1 and reduced histone H3K9 trimethylation responses accompanied by increased acetylation. Importantly, co-treatment with chaetocin and TSA produced potent antileukemic effects in leukemia cells derived from patients. These in vitro findings suggest that combination therapy with SUV39H1 and HDAC inhibitors may be of potential value in the treatment of leukemia.
Acetylation/drug effects
;
Adolescent
;
Adult
;
Aged
;
Apoptosis/*drug effects
;
Cadherins/metabolism
;
Cell Line, Tumor
;
Cyclin-Dependent Kinase Inhibitor p15/metabolism
;
DNA Methylation/drug effects
;
Enzyme Inhibitors/therapeutic use/*toxicity
;
Frizzled Receptors/metabolism
;
Gene Expression Regulation/drug effects
;
HL-60 Cells
;
Histone Deacetylase Inhibitors/therapeutic use/*toxicity
;
Histone-Lysine N-Methyltransferase/*antagonists & inhibitors/metabolism
;
Histones/genetics/metabolism
;
Humans
;
Hydroxamic Acids/therapeutic use/*toxicity
;
K562 Cells
;
Leukemia/drug therapy/metabolism/pathology
;
Leukemia, Myeloid, Acute/genetics/metabolism/pathology
;
Male
;
Middle Aged
;
Piperazines/therapeutic use/toxicity
;
Promoter Regions, Genetic
;
Young Adult
8.Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura.
Soo Young BAE ; Yeo Kyeoung KIM ; Joo Young YOON ; Sung Ji LEE ; Dae Eun KIM ; Sung Yoon REW ; Seung Dok HONG ; Dae Ho JO ; Joon Il HWANG ; Woo Kyun BAE ; Hyun Jeong SHIM ; Jae Sook AHN ; Deok Hwan YANG ; Sang Hee CHO ; Je Jung LEE ; Ik Joo CHUNG ; Hyeoung Joon KIM
Korean Journal of Hematology 2009;44(2):108-112
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea.
Antibodies, Monoclonal, Murine-Derived
;
Blister
;
Epidermal Necrolysis, Toxic
;
Fever
;
Humans
;
Immunoglobulins
;
Korea
;
Leukemia, Lymphocytic, Chronic, B-Cell
;
Lymphoma, Non-Hodgkin
;
Purpura, Thrombocytopenic, Idiopathic
;
Rituximab
9.Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.
Seung Dok HONG ; Yeo Kyeoung KIM ; Hee Nam KIM ; Se Ryeon LEE ; Jae Sook AHN ; Deok Hwan YANG ; Je Jung LEE ; Il Kwon LEE ; Myung Geun SHIN ; Hyeoung Joon KIM
Korean Journal of Hematology 2011;46(1):24-30
BACKGROUND: All-trans retinoic acid (ATRA)/anthracycline chemotherapy is beneficial in newly diagnosed acute promyelocytic leukemia (APL); however, it is important to identify patients with high-risk disease to increase the cure rate. We investigated the outcome of ATRA/anthracycline chemotherapy and clinicobiological correlations of FLT3/ITD and NPM1 mutations in APL patients. METHODS: Induction therapy included oral ATRA (45 mg/m2/day) and idarubicin (12 mg/m2/day, intravenous, on days 2, 4, and 6). Patients achieving complete remission (CR) received 3 courses of ATRA combined with reinforced consolidation therapy. Mutations were analyzed using GeneScan and polymerasae chain reaction assays of bone marrow samples obtained from patients at diagnosis. RESULTS: Forty-five (84.9%) of 53 eligible patients achieved CR. The overall relapse rate was 8.9%, and the 3-year overall survival (OS) and leukemia-free survival (LFS) were 84.9+/-4.9% and 77.5+/-6.0%, respectively. The NPM1 mutation was not found in any patient, while the FLT3/ITD mutation was found in 10 (20.0%) patients. Of the FLT3/ITD+ patients, 80% belonged to the high-risk group, defined according to the presenting WBC and platelet counts. Among the patients who achieved CR, those who were FLT3/ITD+ had a higher relapse rate than those FLT3/ITD-. FLT3/ITD+ patients also had a significantly lower 3-year LFS than FLT3/ITD- patients. Multivariate analysis of the LFS showed that the FLT3/ITD mutation was independently associated with a shorter overall LFS, after adjusting for pretreatment risk stratification. CONCLUSION: This study investigated the clinical outcome of newly diagnosed APL patients treated with ATRA/anthracycline chemotherapy. Patients carrying the FLT3/ITD mutation had more aggressive clinical features and a poorer clinical outcome.
Bone Marrow
;
Drug Therapy, Combination
;
Humans
;
Idarubicin
;
Leukemia, Promyelocytic, Acute
;
Lifting
;
Multivariate Analysis
;
Platelet Count
;
Prognosis
;
Recurrence
;
Treatment Outcome
;
Tretinoin
10.FLT3 Internal Tandem Duplication in Acute Myeloid Leukemia with Normal Karyotype.
Sang Ho KIM ; Yeo Kyeoung KIM ; Il Kwon LEE ; Deog Yeon JO ; Jong Ho WON ; Jae Yong KWAK ; Chang Yeol YIM ; Moo Rim PARK ; Deok Hwan YANG ; Sang Hee CHO ; Je Jung LEE ; Ik Joo CHUNG ; Hyeoung Joon KIM
Korean Journal of Hematology 2007;42(3):250-257
BACKGROUND: The presence of FLT3 internal tandem dupulication (FLT3/ITD) in patients with acute myeloid leukemia (AML) with normal karyotype was investigated in order to evaluate its clinical and prognostic significance. METHODS: The FLT3/ITD was studied by PCR assay in bone marrow samples obtained from 123 patients at diagnosis. Ninety patients who received intensive induction chemotherapy were evaluated. RESULTS: Of total 123 patients, forty-seven (38.2%) demonstrated the aberrant FLT3/ITD. Patients with FLT3/ITD had significantly higher leukocyte counts at presentation than did patients without FLT3/ITD (P=0.04). By multivariate analysis, the FLT3/ITD was an independent prognostic factor of leukemic-free survival (LFS) (P=0.01) in AML patients with normal karyotype. CONCLUSION: This study demonstrated that the presence of the FLT3/ITD was a significant factor for poor prognosis in AML patients with normal karyotype.
Bone Marrow
;
Diagnosis
;
Humans
;
Induction Chemotherapy
;
Karyotype*
;
Leukemia, Myeloid, Acute*
;
Leukocyte Count
;
Multivariate Analysis
;
Polymerase Chain Reaction
;
Prognosis